Suicide and lesser forms of intentional self-harm behaviors produce devastating medical, social and economic costs. Self-harm is integrally related to depressive disorders and Borderline Personality Disorder. Selective Serotonin Reuptake Inhibitors (SSRIs), like escitalopram, are front-line pharmacological treatments for these disorders, putatively regulating depressed mood and reducing suicidality. However, data from case studies and retrospective meta-analyses of depression clinical trials is mixed, with some (but not all ) studies suggesting that during the first months of treatment, SSRIs may increase the risk of suicidal ideation in select individuals, particularly younger individuals. These post-hoc analyses, though informative, are based on studies that provide limited sampling of the self-harm domain. No study, to date, has implemented a direct prospective examination of the effects of early SSRI use on self-harm thoughts and behaviors using a multi-method measurement involving both the laboratory (standard self-aggression paradigm: SAP) and home environments (ecological momentary assessment: EMA). Also, no study has examined the influence of impaired 5-HT function and emotion dysregulation as moderators of outcome with escitalopram. The proposed randomized clinical trial will prospectively assess the impact of eight weeks exposure to SSRI treatment on self-harm ideation and behavior among a sample of 200 subjects with Borderline Personality Disorder and current major depression. After a one week single-blind placebo lead-in, participants will be randomly assigned double blind to either placebo or escitalopram for eight (8) weeks. The primary dependent variable will be EMA of self-harm ideation and behavior obtained several times each day. Self-harm will also be assessed using a laboratory analogue task (SAP) at baseline and again after the eight week trial. Age will be evaluated as a moderator of SSRI response. 5-HT dysfunction and emotion dysregulation will be evaluated as candidate moderators of SSRI response. 5-HT functioning will be assessed using psychophysiological (loudness dependence of the auditory evoked potential: LDAEP) and genetic (5-HT transporter promoter polymorphism: 5-HTTLPR) markers. Measures of emotion dysregulation will include trait aggression, impulsivity and socioemotional information processing. At the conclusion of the eight-week randomized trial, all participants will receive eight weeks of escitalopram administered single-blind, with continued EMA and other assessment.
The proposed randomized clinical trial will prospectively assess the impact of 8 weeks exposure to SSRI treatment on self-harm ideation and behavior among a sample of 200 subjects with Borderline Personality Disorder and current major depression. After a one week single-blind placebo lead-in, participants will be randomly assigned double blind to either placebo or escitalopram daily for eight (8) weeks. The primary dependent variable will be EMA of self-harm ideation and behavior obtained several times each day. Selfharm will also be assessed using a laboratory analogue task (SAP) at baseline and again after the eight week trial. Age, 5-HT dysfunction and emotion dysregulation will be evaluated as potential moderators of SSRI response.
| Ammerman, Brooke A; Jacobucci, Ross; McCloskey, Michael S (2018) Using Exploratory Data Mining to Identify Important Correlates of Nonsuicidal Self-Injury Frequency. Psychol Violence 8:515-525 |
| Burke, Taylor A; Ammerman, Brooke A; Knorr, Anne C et al. (2018) Measuring Acquired Capability for Suicide within an Ideation-to-Action Framework. Psychol Violence 8:277-286 |
| Ammerman, Brooke A; Jacobucci, Ross; Kleiman, Evan M et al. (2017) Development and validation of empirically derived frequency criteria for NSSI disorder using exploratory data mining. Psychol Assess 29:221-231 |
| Puhalla, Alexander A; McCloskey, Michael S; Brickman, Lauren J et al. (2016) Defense styles in Intermittent Explosive Disorder. Psychiatry Res 238:137-142 |
| Ammerman, Brooke A; Burke, Taylor A; Alloy, Lauren B et al. (2016) Subjective pain during NSSI as an active agent in suicide risk. Psychiatry Res 236:80-85 |
| Puhalla, Alexander A; Ammerman, Brooke A; Uyeji, Lauren L et al. (2016) Negative urgency and reward/punishment sensitivity in intermittent explosive disorder. J Affect Disord 201:8-14 |
| Kulper, Daniel A; Kleiman, Evan M; McCloskey, Michael S et al. (2015) The experience of aggressive outbursts in Intermittent Explosive Disorder. Psychiatry Res 225:710-5 |
| Fettich, Karla C; McCloskey, Michael S; Look, Amy E et al. (2015) Emotion regulation deficits in intermittent explosive disorder. Aggress Behav 41:25-33 |
| Fettich, Karla C; McCloskey, Michael S; Look, Amy E et al. (2014) Emotion regulation deficits in intermittent explosive disorder. Aggress Behav : |
| Chen, E Y; Fettich, K C; McCloskey, M S (2012) Correlates of suicidal ideation and/or behavior in bariatric-surgery-seeking individuals with severe obesity. Crisis 33:137-43 |
